Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Po-Ku Chen, Shiow-Jiuan Wey & Der-Yuan Chen. (2022) Interleukin-18: a biomarker with therapeutic potential in adult-onset Still’s disease. Expert Review of Clinical Immunology 18:8, pages 823-833.
Read now
Read now
Dae Hyun Yoo. (2019) Biologics for the treatment of adult-onset still’s disease. Expert Opinion on Biological Therapy 19:11, pages 1173-1190.
Read now
Read now
Dae Hyun Yoo. (2017) Treatment of adult-onset still’s disease: up to date. Expert Review of Clinical Immunology 13:9, pages 849-866.
Read now
Read now
Y-J Ha, E-J Kang, S-W Lee, Y-B Park, S-K Lee, J-S Song & ST Choi. (2015) Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still’s disease. Scandinavian Journal of Rheumatology 44:5, pages 399-403.
Read now
Read now
Dongsheng Hong, Zhihai Yang, Shuyin Han, Xingguang Liang, Kuifen Ma & Xingguo Zhang. (2014) Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Design, Development and Therapy 8, pages 2345-2357.
Read now
Read now
Articles from other publishers (29)
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, Martin Fleck, Norbert Blank, Johannes-Peter Haas, Ina Kötter, Martin Krusche, Gamal Chehab, Bimba Hoyer, Uta Kiltz, Dorothea Fell, Julia Reiners, Christiane Weseloh, Matthias Schneider & Jürgen Braun. (2022) Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guidelineDiagnostik und Behandlung bei M. Still des Erwachsenen: kurze Zusammenfassung der S2-Leitlinie der Deutschen Gesellschaft für Rheumatologie. Zeitschrift für Rheumatologie 82:S2, pages 81-92.
Crossref
Crossref
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, Martin Fleck, Norbert Blank, Johannes-Peter Haas, Ina Kötter, Martin Krusche, Gamal Chehab, Bimba Hoyer, Uta Kiltz, Dorothea Fell, Julia Reiners, Christiane Weseloh, Matthias Schneider & Jürgen Braun. (2022) DGRh-S2e-LeitlinieDGRh S2e guidelines. Zeitschrift für Rheumatologie 81:S1, pages 1-20.
Crossref
Crossref
Arthur Guerber, Etienne Garneret, Thomas El Jammal, Sabine Zaepfel, Mathieu Gerfaud-Valentin, Pascal Sève & Yvan Jamilloux. (2022) Evaluation of Glycosylated Ferritin in Adult-Onset Still’s Disease and Differential Diagnoses. Journal of Clinical Medicine 11:17, pages 5012.
Crossref
Crossref
Nicolas Poursac, Itsaso Odriozola & Marie-Elise Truchetet. (2022) Strategy and Challenges of Paraclinical Examinations in Adult-Onset Still’s Disease. Journal of Clinical Medicine 11:8, pages 2232.
Crossref
Crossref
Yuko Watanabe & Yukie Yamaguchi. (2022) Drug allergy and autoimmune diseases. Allergology International 71:2, pages 179-184.
Crossref
Crossref
Mathilde Harel, Sébastien Fauteux-Daniel, Charlotte Girard-Guyonvarc'h & Cem Gabay. (2022) Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases. Cytokine 150, pages 155781.
Crossref
Crossref
Kuo-Tung Tang, Chia-Wei Hsieh, Hsin-Hua Chen, Yi-Ming Chen, Shih-Hsin Chang, Po-Hao Huang, Joung-Liang Lan & Der-Yuan Chen. (2021) The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clinical Rheumatology 41:2, pages 557-566.
Crossref
Crossref
Charlotte Girard-Guyonvarc’h, Mathilde Harel & Cem Gabay. (2022) The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis. Journal of Clinical Medicine 11:2, pages 430.
Crossref
Crossref
Toshihiko Shiga, Yuji Nozaki, Daisuke Tomita, Kazuya Kishimoto, Yasuaki Hirooka, Koji Kinoshita, Masanori Funauchi & Itaru Matsumura. (2021) Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still’s Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults. Frontiers in Immunology 12.
Crossref
Crossref
Yuning Ma, Jianfen Meng, Jinchao Jia, Mengyan Wang, Jialin Teng, Dehao Zhu, Chengde Yang & Qiongyi Hu. (2021) Current and emerging biological therapy in adult-onset Still’s disease. Rheumatology 60:9, pages 3986-4000.
Crossref
Crossref
Tsai-Ling Liao, Yi-Ming Chen, Kuo-Tung Tang, Po-Ku Chen, Hung-Jen Liu & Der-Yuan Chen. (2021) MicroRNA-223 inhibits neutrophil extracellular traps formation through regulating calcium influx and small extracellular vesicles transmission. Scientific Reports 11:1.
Crossref
Crossref
Petros Efthimiou, Apostolos Kontzias, Peter Hur, Kavita Rodha, G S Ramakrishna & Priscila Nakasato. (2021) Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Seminars in Arthritis and Rheumatism 51:4, pages 858-874.
Crossref
Crossref
Po-Ku Chen & Der-Yuan Chen. (2021) An Update on the Pathogenic Role of Macrophages in Adult-Onset Still’s Disease and Its Implication in Clinical Manifestations and Novel Therapeutics. Journal of Immunology Research 2021, pages 1-11.
Crossref
Crossref
Rui Tian, Xia Chen, Chengde Yang, Jialin Teng, Hongping Qu & Hong-Lei Liu. (2021) Serum Heparin-Binding Protein as a Potential Biomarker to Distinguish Adult-Onset Still’s Disease From Sepsis. Frontiers in Immunology 12.
Crossref
Crossref
Seoung Wan Nam, SuMan Kang, Jun Hyeok Lee & Dae Hyun Yoo. (2021) Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still’s Disease. Journal of Clinical Medicine 10:5, pages 910.
Crossref
Crossref
Tomohiro Koga, Remi Sumiyoshi, Kaori Furukawa, Shuntaro Sato, Kiyoshi Migita, Toshimasa Shimizu, Masataka Umeda, Yushiro Endo, Shoichi Fukui, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Fumiaki Nonaka, Akihiro Yachie, Hideaki Kondo, Takahiro Maeda & Atsushi Kawakami. (2020) Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still’s disease from sepsis. Arthritis Research & Therapy 22:1.
Crossref
Crossref
Robert Z. Harms, Katie R. Ostlund, Monina S. Cabrera, Earline Edwards, Marisa Fisher & Nora Sarvetnick. (2020) Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes. Frontiers in Immunology 11.
Crossref
Crossref
Ken Goda, Tsuneaki Kenzaka, Masahiko Hoshijima, Akihiro Yachie & Hozuka Akita. (2019) Adult-onset Still’s disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review. Rheumatology International 40:1, pages 145-152.
Crossref
Crossref
Stéphane Mitrovic, Eugen Feist & Bruno Fautrel. 2020. Periodic and Non-Periodic Fevers. Periodic and Non-Periodic Fevers
93
132
.
Meng-Yan Wang, Jin-Chao Jia, Cheng-De Yang & Qiong-Yi Hu. (2019) Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review. Chinese Medical Journal 132:23, pages 2856-2864.
Crossref
Crossref
Holger Kudela, Susanne Drynda, Anke Lux, Gerd Horneff & Joern Kekow. (2019) Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatology 3:1.
Crossref
Crossref
Yuko Nariai, Hiroki Kamino, Eiji Obayashi, Hiroaki Kato, Gyosuke Sakashita, Tomoko Sugiura, Kiyoshi Migita, Tomohiro Koga, Atsushi Kawakami, Kazuma Sakamoto, Kenji Kadomatsu, Makoto Nakakido, Kouhei Tsumoto & Takeshi Urano. (2019) Generation and characterization of antagonistic anti-human interleukin (IL)-18 monoclonal antibodies with high affinity: Two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18. Archives of Biochemistry and Biophysics 663, pages 71-82.
Crossref
Crossref
Daisuke Usuda, Yoshiki Furumura, Kento Takeshima, Ryusho Sangen, Yasuhiro Kawai, Yuji Kasamaki, Yoshitsugu Iinuma & Tsugiyasu Kanda. (2018) Interleukin-18 as a diagnostic marker of adult-onset Still’s disease in older patients: a case report and review of the literature. Journal of Medical Case Reports 12:1.
Crossref
Crossref
Eugen Feist, Stéphane Mitrovic & Bruno Fautrel. (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nature Reviews Rheumatology 14:10, pages 603-618.
Crossref
Crossref
Stéphane Mitrovic & Bruno Fautrel. (2018) New Markers for Adult-Onset Still's Disease. Joint Bone Spine 85:3, pages 285-293.
Crossref
Crossref
Stéphane Mitrovic & Bruno Fautrel. (2018) De nouveaux marqueurs pour la maladie de Still de l’adulte. Revue du Rhumatisme 85:2, pages 121-131.
Crossref
Crossref
Dae Hyun Yoo. (2017) Utility and drawbacks of [18]F-fluorodeoxyglucose positron emission tomography in the evaluation of adult-onset Still’s disease. The Korean Journal of Internal Medicine 32:6, pages 998-1001.
Crossref
Crossref
Charlotte Girard, Jürgen Rech, Michael Brown, Danièle Allali, Pascale Roux-Lombard, François Spertini, Eduardo J. Schiffrin, Georg Schett, Bernhard Manger, Sylvette Bas, Greg del Val & Cem Gabay. (2016) Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology 55:12, pages 2237-2247.
Crossref
Crossref
Alexandre Thibault Jacques Maria, Alain Le Quellec, Christian Jorgensen, Isabelle Touitou, Sophie Rivière & Philippe Guilpain. (2014) Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions. Autoimmunity Reviews 13:11, pages 1149-1159.
Crossref
Crossref